Abstract
The unique properties of vesicular stomatitis virus (VSV) make it a promising vaccine platform. With the advent of plasmid-based approaches to generate recombinant VSV viruses that express glycoproteins of other viruses, researchers now have the means to generate vaccine candidates targeting a variety of human pathogens. This chapter gives a general overview of the workings of VSV as a vaccine platform and provides a detailed protocol for the generation of recombinant VSV from plasmids.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Marzi A, Feldmann F, Geisbert TW, Feldmann H, Safronetz D (2015) Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses. Emerg Infect Dis 21(2):305–307
Lichty BD, Power AT, Stojdl DF, Bell JC (2004) Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 10(5):210–216
Geisbert TW, Feldmann H (2011) Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 204(Suppl):S1075–S1081
Fuchs JD, Frank I, Elizaga ML, Allen M, Frahm N, Kochar N, Li S, Edupuganti S, Kalams SA, Tomaras GD, Sheets R, Pensiero M, Tremblay MA, Higgins TJ, Latham T, Egan MA, Clarke DK, Eldridge JH, Mulligan M, Rouphael N, Estep S, Rybczyk K, Dunbar D, Buchbinder S, Wagner T, Isbell R, Chinnell V, Bae J, Escamilla G, Tseng J, Fair R, Ramirez S, Broder G, Briesemeister L, Ferrara A (2015) First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag vaccine (HVTN 090). Open Forum Infect Dis 2(3):ofv082
Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Hossmann S, Kondé MK, Kone S, Kuisma E, Levine MM, Mandal S, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Watson CH, Kéïta S, Kieny MP, Røttingen J-A (2015) Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386(9996):857–866
Huttner A, Dayer J-A, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Krähling V, Kwilas S, Lemaître B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist C-A (2015) The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 15(10):1156–1166
Mire CE, Geisbert JB, Versteeg KM, Mamaeva N, Agans KN, Geisbert TW, Connor JH (2015) A single-vector, single-injection trivalent filovirus vaccine: proof of concept study in outbred guinea pigs. J Infect Dis 212(Suppl):S384–S388
Lawson ND, Stillman EA, Whitt MA, Rose JK (1995) Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A 92:4477–4481
Whitt MA (2010) Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J Virol Methods 169(2):365–374
Fuerst TR, Niles EG, Studier FW, Moss B (1986) Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A 83(21):8122–8126
Buchholz UJ, Finke S, Conzelmann K-K (1999) Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 73(1):251–259
Harty RN, Brown ME, Hayes FP, Wright NT, Schnell MJ (2001) Vaccinia virus-free recovery of vesicular stomatitis virus. J Mol Microbiol Biotechnol 3(4):513–517
Knipe DM, Howley PM (2007) Fields virology, 5th edn. Lippincott Williams & Wilkins, Philadelphia
Barr JN, Whelan SPJ, Wertz GW (2002) Transcriptional control of the RNA-dependent RNA polymerase of vesicular stomatitis virus. Biochim Biophys Acta 1577:337–353
Isaacs SN (ed) (2004) Vaccinia virus and poxvirology: methods in molecular biology, vol 269. Hamana Press, Totowa
Ruedas JB, Perrault J (2009) Insertion of enhanced green fluorescent protein in a hinge region of vesicular stomatitis virus L polymerase protein creates a temperature-sensitive virus that displays no virion-associated polymerase activity in vitro. J Virol 83(23):12241–12252
Ruedas JB, Perrault J (2014) Putative domain-domain interactions in the vesicular stomatitis virus L polymerase protein appendage region. J Virol 88(24):14458–14466
Acknowledgements
The authors acknowledge funding through NIH R21 AI121933 and NIH RO1 to JHC. We also acknowledge support through the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award UC6AI058618.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Ruedas, J.B., Connor, J.H. (2017). Generating Recombinant Vesicular Stomatitis Viruses for Use as Vaccine Platforms. In: Ferran, M., Skuse, G. (eds) Recombinant Virus Vaccines. Methods in Molecular Biology, vol 1581. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6869-5_12
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6869-5_12
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6867-1
Online ISBN: 978-1-4939-6869-5
eBook Packages: Springer Protocols